Is RMD a good stock to buy right now?

Based on our 6-factor quantitative model, RESMED INC (RMD) receives a "Reduce" rating with a composite score of 43.3/100. It is ranked #2,269 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 45/100, Momentum 42/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for RMD?

RESMED INC (RMD) has a "Reduce" rating and 2-star score. The composite score of 43.3 ranks it #2,269 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is RMD in?

RESMED INC operates in the Healthcare sector (Medical Equipment industry) with a market cap of $32.46 billion. It is classified as a large-cap stock.

Does RMD pay a dividend?

Yes, RMD pays a dividend with a current yield of 0.94%. For every $1,000 invested, you would receive approximately $9.40 in annual dividend income.

What is RMD's P/E ratio?

RMD has a trailing P/E ratio of 22.70x. The Healthcare sector average is 23.6x. This P/E is in a moderate range relative to the broader market.

How profitable is RMD?

RMD's quality factor score is 50/100. Gross margin: 60.3%. ROE: 22.9% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is RMD valued compared to peers?

RMD's value factor score is 45/100 (higher = cheaper). Key multiples: P/E 22.7x, EV/EBITDA 18.7x. Valuation is roughly in line with peers.

What is RMD's debt level?

RMD's debt-to-equity ratio is 6%. Sector average: 32%. Low leverage suggests conservative financial management.

RMD has a beta of 0.67, meaning it is less volatile than the market. Stability score: 83/100.

Does RMD have high short interest?

RMD's short interest factor score is 2/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

RMD Stock Analysis: Reduce (Score 43.3/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
RMD	+0.39%	+2.13%	-7.38%	-4.98%	+8.70%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	+0.46%	-1.47%	-7.72%	-4.62%	-20.82%	-	-	-
Alpha vs Sector	+1.74%	+1.79%	-3.57%	-0.14%	-0.51%	-	-	-

Metric	RMD	Benchmark
P/E Ratio	22.7x	-4%
EV/EBITDA	18.7x	+195%
Price / Book	5.2x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
RMD RESMED INC	43	50	45	42	22.7x	23.0%	60.3%	27.2%	16.2%	6.0x	$32.5B

Key Ratio	TTM	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017
Gross Margin %	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%
Operating Margin %	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.2%	0.2%	0.2%
EBITDA Margin %	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
Net Margin %	0.3%	0.3%	0.3%	0.2%	0.2%	0.2%	0.1%	0.2%	0.2%	0.1%	0.2%
FCF Margin %	-	-	-	-	-	-	19.8%	23.9%	15.0%	18.9%	17.0%
ROE %	0.2%	0.1%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
ROA %	0.2%	0.0%	0.2%	0.1%	0.1%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%
ROIC %	0.2%	5.8%	20.1%	18.7%	16.1%	19.2%	22.0%	19.9%	14.3%	19.9%	15.2%

Key Ratio

TTM

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

Gross Margin %

0.6%

Operating Margin %

0.3%

0.2%

EBITDA Margin %

0.3%

Net Margin %

0.3%

0.2%

0.1%

0.2%

0.1%

0.2%

FCF Margin %

19.8%

23.9%

15.0%

18.9%

17.0%

ROE %

0.2%

0.1%

0.2%

ROA %

0.2%

0.0%

0.2%

0.1%

0.2%

0.1%

ROIC %

0.2%

5.8%

20.1%

18.7%

16.1%

19.2%

22.0%

19.9%

14.3%

19.9%

15.2%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$5.3B	$5.1B	$4.7B	$4.2B	$3.6B	$3.2B	$3.0B	$2.6B	$2.3B	$2.1B	$1.8B	$1.7B
	—	$2.1B	$2.0B	$1.9B	$1.6B	—	—	—	—	—	—	—
	$3.2B	$3.1B	$2.7B	$2.4B	$2.0B	$1.8B	$1.7B	$1.5B	$1.4B	$1.2B	$1.1B	$1.0B
Gross Margin	60.3%	59.4%	56.7%	55.8%	56.6%	57.5%	58.1%	57.3%	57.0%	58.1%	58.0%	60.2%
	—	$991M	$917M	$874M	$739M	—	—	—	—	—	—	—
Research & Development	—	$331M	$308M	$288M	$254M	$225M	$202M	$181M	$155M	$144M	$119M	$115M
Depreciation	—	—	—	—	—	$192M	$181M	$151M	$120M	$112M	$87M	$73M
Total Operating Expenses	—	$1.4B	$1.3B	$1.2B	$1.0B	—	—	—	—	—	—	—
	$1.8B	$1.7B	$1.3B	$1.1B	$1.0B	$904M	$810M	$579M	$542M	$426M	$429M	$409M
EBIT	$1.8B	$1.7B	$1.3B	$1.1B	$1.0B	$904M	$810M	$579M	$542M	$426M	$429M	$409M
EBITDA	$1.8B	$1.7B	$1.3B	$1.1B	$1.0B	$1.1B	$979M	$719M	$653M	$542M	$521M	$489M
Operating Margin	33.4%	32.8%	28.2%	26.8%	28.0%	28.3%	27.4%	22.2%	23.2%	20.6%	23.3%	24.4%
EBITDA Margin	33.4%	32.7%	28.2%	26.8%	28.0%	34.7%	33.1%	27.6%	27.9%	26.2%	28.3%	29.1%
	—	—	—	—	—	$24M	$39M	$36M	$28M	$28M	$11M	$6M
	—	$1.7B	$1.3B	$1.1B	$960M	—	—	—	—	—	—	—
Income Tax Expense	—	$277M	$244M	$204M	$181M	$409M	$111M	$114M	$206M	$76M	$87M	$83M
	$1.5B	$1.4B	$1.0B	$898M	$779M	$475M	$622M	$405M	$316M	$342M	$352M	$353M
Net Margin	27.2%	27.2%	21.8%	21.3%	21.8%	14.8%	21.0%	15.5%	13.5%	16.6%	19.2%	21.0%
	$2.69	$9.55	$6.94	$6.12	$5.34	$3.27	$4.31	$2.83	$2.21	$2.42	$2.51	$2.51
Diluted EPS	$2.69	$9.51	$6.92	$6.09	$5.30	$3.27	$4.31	$2.83	$2.21	$2.42	$2.51	$2.51
Weighted Avg Basic	—	147M	147M	147M	146M	—	—	—	—	—	—	—
Weighted Avg Diluted	—	147M	148M	147M	147M	—	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$5.3B

$5.1B

$4.7B

$4.2B

$3.6B

$3.2B

$3.0B

$2.6B

$2.3B

$2.1B

$1.8B

$1.7B

—

$2.1B

$2.0B

$1.9B

$1.6B

—

$3.2B

$3.1B

$2.7B

$2.4B

$2.0B

$1.8B

$1.7B

$1.5B

$1.4B

$1.2B

$1.1B

$1.0B

Gross Margin

60.3%

59.4%

56.7%

55.8%

56.6%

57.5%

58.1%

57.3%

57.0%

58.1%

58.0%

60.2%

—

$991M

$917M

$874M

$739M

—

Research & Development

—

$331M

$308M

$288M

$254M

$225M

$202M

$181M

$155M

$144M

$119M

$115M

Depreciation

—

$192M

$181M

$151M

$120M

$112M

$87M

$73M

Total Operating Expenses

—

$1.4B

$1.3B

$1.2B

$1.0B

—

$1.8B

$1.7B

$1.3B

$1.1B

$1.0B

$904M

$810M

$579M

$542M

$426M

$429M

$409M

EBIT

$1.8B

$1.7B

$1.3B

$1.1B

$1.0B

$904M

$810M

$579M

$542M

$426M

$429M

$409M

EBITDA

$1.8B

$1.7B

$1.3B

$1.1B

$1.0B

$1.1B

$979M

$719M

$653M

$542M

$521M

$489M

Operating Margin

33.4%

32.8%

28.2%

26.8%

28.0%

28.3%

27.4%

22.2%

23.2%

20.6%

23.3%

24.4%

EBITDA Margin

33.4%

32.7%

28.2%

26.8%

28.0%

34.7%

33.1%

27.6%

27.9%

26.2%

28.3%

29.1%

—

$24M

$39M

$36M

$28M

$11M

$6M

—

$1.7B

$1.3B

$1.1B

$960M

—

Income Tax Expense

—

$277M

$244M

$204M

$181M

$409M

$111M

$114M

$206M

$76M

$87M

$83M

$1.5B

$1.4B

$1.0B

$898M

$779M

$475M

$622M

$405M

$316M

$342M

$352M

$353M

Net Margin

27.2%

21.8%

21.3%

21.8%

14.8%

21.0%

15.5%

13.5%

16.6%

19.2%

21.0%

$2.69

$9.55

$6.94

$6.12

$5.34

$3.27

$4.31

$2.83

$2.21

$2.42

$2.51

Diluted EPS

$2.69

$9.51

$6.92

$6.09

$5.30

$3.27

$4.31

$2.83

$2.21

$2.42

$2.51

Weighted Avg Basic

—

147M

146M

—

Weighted Avg Diluted

—

147M

148M

147M

—

RESMED INC (RMD) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does RESMED INC Do?

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; and connectivity module and propeller solutions. In addition, it offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice agencies, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. RESMED INC (RMD) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Michael J. Farrell and employs approximately 8,160 people, headquartered in SAN DIEGO, California. With a market capitalization of $32.5B, RMD is one of the prominent companies in the Healthcare sector.

RESMED INC (RMD) Stock Rating — Reduce (April 2026)

As of April 2026, RESMED INC receives a Reduce rating with a composite score of 43.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.RMD ranks #2,269 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, RESMED INC ranks #266 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RMD Stock Price and 52-Week Range

RESMED INC (RMD) currently trades at $228.87. The stock gained $0.89 (0.4%) in the most recent trading session. The 52-week high for RMD is $293.81, which means the stock is currently trading -22.1% from its annual peak. The 52-week low is $199.92, putting the stock 14.5% above its annual trough. Recent trading volume was 844K shares, suggesting relatively thin trading activity.

Is RMD Overvalued or Undervalued? — Valuation Analysis

RESMED INC (RMD) carries a value factor score of 45/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 22.70x, compared to the Healthcare sector average of 23.63x — a discount of 4%. The price-to-book ratio stands at 5.21x, versus the sector average of 2.75x. The price-to-sales ratio is 6.18x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, RMD trades at 18.71x EV/EBITDA, versus 6.34x for the sector.

Overall, RMD's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

RESMED INC Profitability — ROE, Margins, and Quality Score

RESMED INC (RMD) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 22.9%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 17.1% versus the sector average of -33.1%.

On a margin basis, RESMED INC reports gross margins of 60.3%, compared to 71.5% for the sector. The operating margin is 33.4% (sector: -66.1%). Net profit margin stands at 27.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 16.2% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

RMD Debt, Balance Sheet, and Financial Health

RESMED INC has a debt-to-equity ratio of 6.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.06x, indicating strong short-term liquidity. Total debt on the balance sheet is $404M.

RMD has a beta of 0.67, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for RESMED INC is 83/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

RESMED INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, RESMED INC reported revenue of $5.33B and earnings per share (EPS) of $2.69. Net income for the quarter was $1.45B. Gross margin was 60.3%. Operating income came in at $1.78B.

In Q2 2026, RESMED INC reported revenue of $1.42B and earnings per share (EPS) of $2.69. Net income for the quarter was $393M. Gross margin was 61.8%. Revenue grew 11.0% year-over-year compared to Q2 2025. Operating income came in at $492M.

In Q1 2026, RESMED INC reported revenue of $1.34B and earnings per share (EPS) of $2.38. Net income for the quarter was $349M. Gross margin was 61.5%. Revenue grew 9.1% year-over-year compared to Q1 2025. Operating income came in at $447M.

In FY 2025, RESMED INC reported revenue of $5.15B and earnings per share (EPS) of $9.55. Net income for the quarter was $1.40B. Gross margin was 59.4%. Revenue grew 9.8% year-over-year compared to FY 2024. Operating income came in at $1.69B.

Over the past 8 quarters, RESMED INC has demonstrated a growth trajectory, with revenue expanding from $4.69B to $5.33B. Investors analyzing RMD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RMD Dividend Yield and Income Analysis

RESMED INC (RMD) currently pays a dividend yield of 0.9%. At this yield, a $10,000 investment in RMD stock would generate approximately $$94.00 in annual dividend income. With a net margin of 27.2%, the dividend appears well-covered by earnings, suggesting sustainable payouts going forward.

RMD Momentum and Technical Analysis Profile

RESMED INC (RMD) has a momentum factor score of 42/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

RMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, RESMED INC (RMD) ranks #266 out of 838 stocks based on the Blank Capital composite score. This places RMD in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RMD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RMD vs S&P 500 (SPY) comparison to assess how RESMED INC stacks up against the broader market across all factor dimensions.

RMD Next Earnings Date

No upcoming earnings date has been announced for RESMED INC (RMD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RMD? — Investment Thesis Summary

The quantitative profile for RESMED INC suggests caution. Low volatility (stability score 83/100) reduces downside risk.

In summary, RESMED INC (RMD) earns a Reduce rating with a composite score of 43.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RMD stock.

Related Resources for RMD Investors

Explore more research and tools: RMD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RMD head-to-head with peers: RMD vs AZN, RMD vs SLGL, RMD vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

I Shared 42 Sell Ratings In 2019. Here Is How They Have Performed Long-Term.

A world away from Kuta: New Bali resort’s big selling point? Sleep

Citigroup Maintains Buy on ResMed, Lowers Price Target to $340

How to invest $300 a month in Australian shares to target a $50,000 annual second income

ResMed Insider Selling Raises Questions On Management Conviction And Valuation

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

RESMED INC (RMD) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does RESMED INC Do?

RESMED INC (RMD) Stock Rating — Reduce (April 2026)

RMD Stock Price and 52-Week Range

Is RMD Overvalued or Undervalued? — Valuation Analysis

RESMED INC Profitability — ROE, Margins, and Quality Score

RMD Debt, Balance Sheet, and Financial Health

RESMED INC Revenue and Earnings History — Quarterly Trend

RMD Dividend Yield and Income Analysis

RMD Momentum and Technical Analysis Profile

RMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

RMD Next Earnings Date

Should You Buy RMD? — Investment Thesis Summary

Related Resources for RMD Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

I Shared 42 Sell Ratings In 2019. Here Is How They Have Performed Long-Term.

A world away from Kuta: New Bali resort’s big selling point? Sleep

Citigroup Maintains Buy on ResMed, Lowers Price Target to $340

How to invest $300 a month in Australian shares to target a $50,000 annual second income

ResMed Insider Selling Raises Questions On Management Conviction And Valuation